Omni Ab Status
The company was acquired by Ligand Pharmaceuticals (NAS:LGND) for $178 million on December 29, 2015. The deal included $92.6 million in cash and $85.4 million in Ligand common stock.
Developer of human monoclonal antibody platforms. The company develops human therapeutic antibodies based on transgenic rats for pharmaceutical companies.
Year Founded
2007
General Information
-
Website
-
Business Status
Profitable
-
Ownership Status
Acquired/Merged (Operating Subsidiary)
-
Financing Status
Formerly VC-backed
Omni Ab News and Updates
Did you hear about these 34 funding rounds this week?
FinTech Global | February 3, 2023
TaskUs, Inc. (NASDAQ:TASK) Given Average Rating of "Hold" by ...
MarketBeat | February 1, 2023
Cision Announces Cali Tran as New CEO USA - English
PR Newswire | January 31, 2023
Anheuser-Busch Super Bowl LVII Starting Line-Up Revealed - Anheuser
Anheuser-Busch | January 19, 2023
2023 Spring Preview: Nonfiction, Part one
Quill & Quire | January 18, 2023
2023 Spring Preview: Fiction and Poetry
Quill & Quire | January 11, 2023
Omni Ab Primary Industry Sector / Group / Code
Omni Ab's Trends
Headquarters
-
HQ Address Line 12747 Ross Road
-
HQ Address Line 2Suite A
-
HQ CityPalo Alto
-
HQ State/ProvinceCalifornia
-
HQ Post Code94303
-
HQ CountryUnited States
Omni Ab's Keywords
mood_badFeed is empty.
Add a review